IOL Chemicals & Pharmaceuticals Ltd (IOLCP) has the bragging rights of being the world’s largest manufacturer of Ibuprofen (yes, the painkiller you pop after reading quarterly results). But while the product reduces headaches, the company’s financials have been giving them to investors. The stock trades at ₹100 with a P/E of 29—modest compared to pharma peers but high considering falling profits. Revenue growth has been a snail at 1.9% over 5 years, and ROE has slipped to a sad 6%. The only thing consistent is their dividend, which they use as a pain balm for shareholders.
Introduction
If there were a pharma Oscar for “Best One-Hit Wonder,” IOLCP would win hands down. With a global Ibuprofen market share of 35%, they practically control your pain relief. However, their own business seems to be in chronic pain. From a roaring FY20 with 30% OPM, they’ve slipped into single-digit margins. Sales are stagnating, profits have shrunk, and growth charts look flatter than a paracetamol tablet.
Investors hope for a turnaround, but till then, the company remains the stock market’s version of a pain management clinic: relieving others’ pain while suffering its own.
Business Model (WTF Do They Even Do?)
IOLCP operates in two main segments:
Pharmaceuticals (APIs): Dominated by Ibuprofen, which accounts for a large chunk of revenue.
Specialty Chemicals: Supplies intermediates used in pharma and agrochemicals.
They sell to domestic and export markets, with a strong presence in regulated markets. However, over-dependence on a single product (Ibuprofen) makes them vulnerable to pricing pressure.
Verdict: A one-trick pony with a diamond saddle—still a pony.
Financials Overview
Numbers reveal the true painkiller story:
Year
Revenue (₹ Cr.)
EBITDA (₹ Cr.)
PAT (₹ Cr.)
Growth
FY23
2,217
227
140
-16% PAT
FY24
2,133
232
135
-3% PAT
FY25
2,079
202
101
-25% PAT
P/E (fresh): EPS FY25 ₹3.44, Price ₹100 → P/E ~29 (fair but not cheap).
Margins: OPM down to 10%, once was 30%.
Cash from operations: Positive but shrinking (₹179 Cr. in FY25).
Commentary: From superstar to struggling—think Shah Rukh Khan in the “Zero” phase.
